NCT03023826View on ClinicalTrials.gov

A Study of LY3202626 in Healthy Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 15, 2017

Primary Completion Date

April 4, 2017

Study Completion Date

April 4, 2017

Conditions
Healthy
Interventions
DRUG

LY3202626 (R-Fasting)

Administered orally

DRUG

LY3202626 (T1-Fasting)

Administered orally

DRUG

LY3202626 (T1-Fed)

Administered orally

Trial Locations (1)

117597

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician., Singapore

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT03023826 - A Study of LY3202626 in Healthy Participants | Biotech Hunter | Biotech Hunter